TETRAULT LYNN A. 4

What Happened

• Lynn A. Tetrault, a director of Neogenomics, reported exercises/conversions of derivatives and receipt of awards on 2026-06-01. The filing shows: 23,077 shares acquired via exercise/conversion (code M) and a simultaneous disposition of 23,077 derivative shares (code M), plus awards/grants of 11,069 and 15,970 shares (codes A). All transactions show a $0.00 price (no cash paid).
• Gross acquired shares = 50,116; disposed shares = 23,077; net increase = 27,039 shares. Reported total value for these entries is $0 (reflects conversion/award form, not open-market purchase or sale proceeds).

Key Details

• Transaction date(s): 2026-06-01. Form filed: 2026-06-03 (Accession 0001628280-26-040578).
• Prices: all entries reported at $0.00 per share; total dollar amount shown = $0.
• Specific entries: M — 23,077 shares acquired; M — 23,077 shares disposed (derivative); A — 11,069 shares acquired (derivative, RSU release per footnote); A — 15,970 shares acquired (derivative, RSU release).
• Net share change from these reported transactions: +27,039 shares.
• Shares owned after transaction: not provided in the supplied data.
• Footnotes: F1 — release of restricted stock units previously reported on a Form 4; F2 — once vested, the shares of common stock are not subject to expiration.
• Filing timeliness: no late filing indicated in the provided data.

Context

• Codes: M = exercise/conversion of a derivative, A = grant/award/acquisition. The $0.00 price and footnotes indicate these were conversions/releases of previously granted awards (RSUs) rather than open-market purchases or cash sales. Such awards are typically administrative/compensation events; they do not by themselves signal a purchase-funded bullish bet.